Emergent BioSolutions Inc.

Form 4

Common

Common

Stock

Stock

September 24, 2008

September 2	24, 2008											
FORM 4 LINITED STATES SECURITIES AND EXCHANGE COMMISSION								AT .	OMB APPROVAL			
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549								N OMB Number	. 3235-0287			
Check this box							Expires:	January 31				
if no lor subject Section Form 4	to SIAIEN 16. or	CHANGES IN BENEFICIAL OW SECURITIES						Estimate burden l respons	ed average nours per			
Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940												
(Print or Type Responses)												
1. Name and Address of Reporting Person * El-Hibri Fuad			2. Issue Symbol	er Name an	d Ticker o	r Trac	ling	5. Relationship of Reporting Person(s) to Issuer				
			Emergent BioSolutions Inc. [EBS]					(Check all applicable)				
(Last)	(First) (Middle)	3. Date of Earliest Transaction									
2273 RESEARCH BLVD, SUITE 400			(Month/Day/Year) 09/22/2008					_X_ Director _X_ 10% Owner _X_ Officer (give title Other (specify below) CEO & Chairman				
F				4. If Amendment, Date Original Filed(Month/Day/Year)				6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting				
ROCKVILLE, MD 20850 — Form thed by More than One Reporting Person												
(City)	(State)	(Zip)	Tab	ole I - Non-	Derivative	e Secu	ırities Ac	quired, Disposed	of, or Benefi	cially Owned		
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deem Execution any (Month/Da	Date, if	3. Transactio Code (Instr. 8)		ties Acquired sposed of (D) 4 and 5)		5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
Common Stock	09/22/2008			Code V $S_{\underline{(1)}}$	Amount 6,700	(D)	Price \$ 14.02	7,781,835 (1)	I	By Intervac, L.L.C.		
Common Stock								246,992	D			
Common Stock								3,665,043 (2)	I	By BioPharm, L.L.C.		

By Biovac,

By Intervac

Managment,

L.L.C.

1,599,155 (3) I

719,275 (4)

L.L.C.

SEC 1474

(9-02)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	4. Transact Code (Instr. 8)	5. ionNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		ate	7. Titl Amou Under Secur (Instr.	int of rlying	8. Price of Derivative Security (Instr. 5)	9 1 S 1 C 1 T
			Code V	7 (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

Reporting Owners

Reporting Owner Name / Address	Relationships						
• 0	Director	10% Owner	Officer	Other			
El-Hibri Fuad 2273 RESEARCH BLVD, SUITE 400 ROCKVILLE, MD 20850	X	X	CEO & Chairman				

Signatures

/s/ Joseph J. Kaufman, attorney-in-fact 09/24/2008

**Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Intervac, L.L.C. on June 13, 2008.

Intervac, L.L.C. was the direct owner of the shares of Common Stock sold pursuant to the Rule 10b5-1 trading plan, and was or is the direct owner of the shares of Common Stock reported as beneficially owned immediately following each of the reported sales. Both before and after the reported sales, Mr. El-Hibri held, individually and with his wife, as tenants by the entirety, an aggregate 38.0276% equity interest in Intervac, L.L.C. Mr. El-Hibri disclaims beneficial ownership of the shares of Common Stock directly owned by Intervac, L.L.C. for purposes of Section 16, except to the extent of his pecuniary interest therein.

Reporting Owners 2

ice of 9. Nuvative Derivity Security Security 5. 5)

Own-Follo Repo Trans (Instr

tionships

Edgar Filing: Emergent BioSolutions Inc. - Form 4

- Mr. El-Hibri is the holder of a 40.17% (567,582.3 units) equity interest in BioPharm, L.L.C. BioPharm, L.L.C. is the direct owner of 3,665,043 shares of Common Stock. Mr. El-Hibri disclaims beneficial ownership of these shares for purposes of Section 16, except to the extent of his pecuniary interest in 1,472,248 shares.
- Mr. El-Hibri holds with his wife, as tenants by the entirety, a 89.2% equity interest in Biovac, L.L.C. Biovac, L.L.C. is the direct owner of (3) 1,599,155 shares of Common Stock. Mr. El-Hibri disclaims beneficial ownership of these shares for purposes of Section 16, except to the extent of his pecuniary interest in 1,426,446 shares.
 - Mr. El-Hibri holds with his wife, as tenants by the entirety, a 31.11% equity interest in Intervac Management, L.L.C. Intervac
- (4) Management, L.L.C. is the direct owner of 719,275 shares of Common Stock. Mr. El-Hibri disclaims beneficial ownership of these shares for purposes of Section 16, except to the extent of his pecuniary interest in 223,766 shares.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.